Payment overview · 2025
General Payments
$333.50
16 reported records · 8 companies
Healthcare provider profile · identity verified
James Hoover, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HILLIARD, OH · NPI 1386987741
Verified facts
What the public records show
CMS Open Payments records show James Hoover, M.D. received $333.50 in general payments during 2025 across 16 reported records.
Astellas Pharma US Inc accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $71.43 | 21.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.09 | 20.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.78 | 18.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.13 | 12.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.67 | 9.8% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $19.02 | 5.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.93 | 5.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $17.45 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $333.50 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $71.43 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.64 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.13 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.13 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 14 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 52 |
| Lisinopril | Lisinopril | 189 | 55 |
| Simvastatin | Simvastatin | 182 | 49 |
| Losartan Potassium | Losartan Potassium | 159 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 48 |
| Trazodone Hcl | Trazodone Hcl | 135 | 41 |
| Sertraline Hcl | Sertraline Hcl | 132 | 36 |
| Omeprazole | Omeprazole | 128 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 29 |
| Prednisone | Prednisone | 120 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 38 |
| Alendronate Sodium | Alendronate Sodium | 117 | 39 |
| Eliquis | Apixaban | 117 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 30 |
| Allopurinol | Allopurinol | 88 | 27 |
| Metformin Hcl Er | Metformin Hcl | 76 | 26 |
| Gabapentin | Gabapentin | 74 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 19 |
| Meloxicam | Meloxicam | 69 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 15 |
| Azithromycin | Azithromycin | 56 | 52 |
| Alprazolam | Alprazolam | 55 | 18 |
| Celecoxib | Celecoxib | 53 | 27 |
| Valsartan | Valsartan | 52 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 43 |
| Lorazepam | Lorazepam | 49 | 11 |
| Atenolol | Atenolol | 47 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 39 |
| Finasteride | Finasteride | 45 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 24 |
| Ezetimibe | Ezetimibe | 43 | 14 |
| Furosemide | Furosemide | 43 | 17 |
| Montelukast Sodium | Montelukast Sodium | 42 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Carvedilol | Carvedilol | 40 | 11 |
| Metformin Hcl | Metformin Hcl | 39 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 14 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 11 |
| Ozempic | Semaglutide | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 32 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Cefdinir | Cefdinir | 28 | 23 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | 11 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Naproxen | Naproxen | 19 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | 14 |
| Estradiol | Estradiol | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $333.50 · 16 records | Astellas Pharma US Inc | ABRYSVO, DUPIXENT, Doc Band, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, Xhance | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error